Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-11-13
2007-11-13
Morris, Patricia L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S277400
Reexamination Certificate
active
10477382
ABSTRACT:
The use of 3-[1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl]-6-chloro-1H-indole, any of its enantiomers and pharmaceutically acceptable salts thereof for the preparation of a pharmaceutical composition for the treatment of attention deficit hyperactivity disorder.
REFERENCES:
patent: 5521197 (1996-05-01), Audia
patent: 6262087 (2001-07-01), Perregaard et al.
patent: 6656953 (2003-12-01), Hoemann
patent: WO-98/28293 (1998-07-01), None
Tarazi et al. I, “Dopamine D4 receptos, etc.,” Molecular Psychiatry, 1999, 4, 529-538.
Paterson et al., “Dopamine D4 Receptor, etc.,” Neuropsychopharmacology, 1999, 21 (1) 3-16.
Todd et al., “The dopamine receptor, etc.,” Trends in Pharmacological Sciences 22 (2), 2001, 55-56.
Tarazi et al., II, “Dopamine D4 Receptors, etc.,” Journal of Receptors and Signal Transduction, 24 (3), 2004, 131-147.
J.T. McCracken, et al., “Evidence for linkage of a tandem duplication polymorphism upstream of the dopamine D4 receptor gene (DRD4) with attention deficit hyperactivity disorder (ADHD)”, Molecular Psychiatry, vol. 5, (2000), pp. 531-536.
Arnt Jorn
Hertel Klaus Peter
Darby & Darby
H. Lundbeck A/S
Morris Patricia L.
LandOfFree
Treatment of ADHD does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of ADHD, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of ADHD will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3830803